Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of alogliptin, a DPP-4 inhibitor, in patients with type 2 diabetes: a 3-year prospective, controlled, observational study (J-BRAND Registry).
Ueki K, Tanizawa Y, Nakamura J, Yamada Y, Inagaki N, Watada H, Shimomura I, Nishimura R, Miyoshi H, Abiko A, Katagiri H, Hayashi M, Shimada A, Naruse K, Fujimoto S, Fujiwara M, Shikata K, Okada Y, Araki E, Yamazaki T, Kadowaki T; J-BRAND Registry Group. Ueki K, et al. Among authors: tanizawa y. BMJ Open Diabetes Res Care. 2021 Jan;9(1):e001787. doi: 10.1136/bmjdrc-2020-001787. BMJ Open Diabetes Res Care. 2021. PMID: 33441417 Free PMC article.
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Araki E, et al. Among authors: tanizawa y. Diabetes Care. 2018 Mar;41(3):538-546. doi: 10.2337/dc17-1589. Epub 2018 Jan 3. Diabetes Care. 2018. PMID: 29298800 Clinical Trial.
Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010: Report of the Committee on Causes of Death in Diabetes Mellitus.
Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, Ueki K, Nakayama T. Nakamura J, et al. Among authors: tanizawa y. J Diabetes Investig. 2017 May;8(3):397-410. doi: 10.1111/jdi.12645. Epub 2017 Mar 27. J Diabetes Investig. 2017. PMID: 28349643 Free PMC article.
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Araki E, et al. Among authors: tanizawa y. Diabetes Obes Metab. 2019 Jul;21(7):1737-1744. doi: 10.1111/dom.13686. Epub 2019 Apr 1. Diabetes Obes Metab. 2019. PMID: 30830727 Free PMC article. Clinical Trial.
Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K, Araki E, Tanizawa Y, Ross Agner B, Nishida T, Ranthe M, Inagaki N. Kaku K, et al. Among authors: tanizawa y. Diabetes Obes Metab. 2019 Dec;21(12):2674-2683. doi: 10.1111/dom.13856. Epub 2019 Aug 28. Diabetes Obes Metab. 2019. PMID: 31407845 Free PMC article. Clinical Trial.
Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study.
Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M, Imaoka T. Araki E, et al. Among authors: tanizawa y. Diabetes Obes Metab. 2015 Oct;17(10):994-1002. doi: 10.1111/dom.12540. Epub 2015 Aug 20. Diabetes Obes Metab. 2015. PMID: 26179754 Free PMC article. Clinical Trial.
393 results